European Commission logo
English English
CORDIS - EU research results
Content archived on 2024-05-29

Development of early non-invasive biomarkers and means for the diagnosis and progression monitoring of pre-eclampsia and tailoring putative therapies


Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death. We will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET; and assess & characterize plausible links between marker shortage/access, PET & putative medications in in vitro systems to fit putative medications to pre-defined disease-risk women. Candidates for 1st trimester risk prediction of PET (cell free DNA & RNA, serum PP13, ADAM12, PAPP-A) will be verified with new ones using genomics & proteomics. Our blood, urine & fixed placenta tissue banks of pregnant women enable comparative analysis to build integrative, non-invasive Marker Effectiveness Profiles (MEPs) to PET subtypes (early/late onset, mild/severe, HELLP & IUGR). Disease progressions will be detected by continuous marker monitoring. Expertise in trophoblast in-vitro systems (placenta explants & cell lines) and quantitative real time PCR, genomics & proteomics, immunohistochemistry & confocal microscopy will verify markers' roles and identify links to curing effects of putative medications. We will model 'Putative Medication Benefit Arrays' (PMBAs) for PET subtypes matched to MEPs. We will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. Trans-European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings. R&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia.'

Call for proposal

See other projects for this call


EU contribution
No data
2 Ha'Carmel Street

See on map

Total cost
No data

Participants (10)